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Heterologous prime-boost regimens utilizing BCG as a prime vaccine probably represent the best hope for the development
of novel tuberculosis (TB) vaccines. In this study, we examined the immunogenicity and protective eﬃcacy of DNA vaccine
(pcD685A) expressing the fusion protein of Ag85A and ESAT-6 (r685A) and its booster eﬀects in BCG-immunized mice. The
recombinant r685A fusion protein stimulated higher level of antigen-speciﬁc IFN-γ release in tuberculin skin test- (TST-) positive
healthy household contacts of active pulmonary TB patients than that in TST-negative population. Vaccination of C57BL/6 mice
withpcD685A resulted insigniﬁcantprotection againstchallengewithvirulentMycobacterium tuberculosis H37Rvwhencompared
with the control group. Most importantly, pcD685A could act as a BCG booster and amplify Th1-type cell-mediated immunityin
t h el u n go fB C G - v a c c i n a t e dm i c ea ss h o w nt h ei n c r e a s e de x p r e s s i o no fI F N - γ. The most signiﬁcant reduction in bacterial load of
both spleen and lung was obtained in mice vaccinated with BCG prime and pcD685A DNA booster when compared with BCG
or pcD685A alone. Thus, our study indicates that pcD685A may be an eﬃcient booster vaccine against TB with a strong ability to
enhance prior BCG immunity.
1.Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis,i s
a leading infectious killer worldwide [1]. The emergence and
spread of multidrug-resistant TB (MDR-TB) and extensively
drug-resistant TB (XDR-TB) and coinfection with TB/HIV
pose serious challenges to eﬀective TB control [2]. M. bovis
BCG is currently the only available vaccine against TB,
with over 120 million doses administered annually [3]. BCG
immunization provides protection against severe forms of
TBinchildren,includingtuberculousmeningitisandmiliary
TB [4]. However, BCG induced-protection lasts less than
15 years because antituberculous protective immunity wanes
gradually after the initial immunization [5]. Consequently,
developing new, more eﬀective vaccines and immunization
strategies aimed to boost waning BCG-induced protective
responses, is urgently needed.
DNA vaccines can stimulate both humoral and cell-
mediated immunity in diﬀerent animal models of TB and
is thought to be a promising strategy in the development
of new vaccines against TB [6]. DNA vaccine candidates
expressing several antigens of M. tuberculosis have been
shown to provide protective immune responses against TB
[6] and to boost BCG eﬃcacy using prime/boost strategies
[7]. In our previous study, we constructed two DNA vaccine
candidates separately encoding antigen Ag85A and ESAT-6
from M. tuberculosis, and both DNA vaccines could induce
strong humoral and cell-mediated immunity in vaccinated
mice, which resulted in some degree of protection in mice
challenged with virulent M. tuberculosis [8]. DNA vaccine2 Clinical and Developmental Immunology
expressing ESAT-6 protein could enhance the protective
eﬃcacy of BCG vaccination in mice vaccinated with a
combination strategy of BCG and DNA vaccine [9]. In the
present study, we evaluated the immune responses generated
against DNA vaccine expressing the fusion protein of ESAT-
6 and Ag85A (r685A) and the immunogenicity of r685A
fusionproteinintuberculinskintest-(TST-)positivehealthy
populations. In addition, we evaluated the use of a BCG
prime plus DNA vaccine in a prime/boost strategy to induce
protection against virulent M. tuberculosis challenge in mice.
2.Materialsand Methods
2.1. Bacterial Strain and Culture Media. Escherichia coli
DH5α and BL21 (DE3) strains were used for cloning and
overexpression, respectively. Both bacteria were cultured in
Luria-Bertani (LB) medium with or without agar. When
required, ampicillin was added to a ﬁnal concentration of
100μg/mL. M. tuberculosis H37Rv and M. bovis BCG China
were cultivated inMiddlebrook 7H9 mediumorenumerated
on 7H11 agar (BD, Sparks, USA), supplemented with 10%
ADC, 0.5% glycerol, and 0.05% Tween 80.
2.2. Construction of Recombinant Plasmids. Genes coding
ESAT-6 (esxA, Rv3875) and Ag85A (fbpA, Rv3804c)w e r e
ampliﬁed, respectively, by PCR with primers (listed in
Table 1)a n dt h eg e n o m i cD N Ao fM. tuberculosis H37Rv as
the template. The gene encoding the fusion protein of ESAT-
6 and Ag85A was generated by a second PCR according to
the gene splicing with the overlap extension (GeneSOEing)
method [10]. The PCR products were ﬁrst digested with
BamHI and EcoRI and then cloned into the corresponding
sites of prokaryotic expression vector pProEXHTb (Invitro-
gen, Carlsbad, CA, USA) and eukaryotic expression vector
pcDNA3.1(+), resulting in recombinant plasmids named
pPro685A and pcD685A, respectively. The correctness of
recombinant plasmids was conﬁrmed by DNA sequencing
andenzyme digestion. Plasmids pcDNA3.1(+)and pcD685A
for DNA immunization were transformed into competent
Escherichia coliDH5α, and endotoxin-free plasmid DNAwas
puriﬁedusingtheQiagenPlasmidGigakit(Qiagen,Valencia,
CA) according to the manufacturer’s instructions.
2.3. Overexpression of r685A Protein in E. coli. E. coli BL21
(DE3) strain harboring the plasmid pPro685A was cultured
overnight. Overnight cultures were inoculated into fresh
LB medium (1:100) containing ampicillin and incubated
at 37◦C with shaking, until OD600 nm reached 0.6. The
expression of the fusion protein r685A was induced with
isopropyl thio-β-D-galactoside (IPTG) at a ﬁnal concentra-
tion of 0.1mM for 0, 2, 4, or 6 hours. Bacterial pellets were
collected by centrifugation, prepared in sample buﬀer, and
subjected to SDS-PAGE analysis. Proteins were stained with
a Coomassie blue dye.
Puriﬁcation of r685A protein was performed using
the Ni-NTA Puriﬁcation System according to the manual
instructions (Invitrogen, USA). The puriﬁed r685A pro-
tein was lyophilized and diluted in normal saline, using
pyrogen-free reagents, and tested to exclude endotoxin
contamination. The protein concentration was determined
by using the Enhanced BCA Protein Assay Kit (Beyotime
Institute of Biotechnology, Haimen, China) and stored at
−20◦C.
To verify the speciﬁcity of puriﬁed r685A fusion pro-
tein, the protein samples were ﬁrst separated by SDS-
PAGE and then transferred onto nitrocellulose membranes
and probed with a rabbit polyclonal antibody to ESAT-6
(Abcam 45073, Cambridge Science Park, Cambridge, UK)
and a chicken polyclonal antibody to Ag85A (Abcam 36731,
Cambridge Science Park, Cambridge, UK) as the primary
antibody. Alkaline phosphatase-conjugated goat antirabbit
IgG antibody and rabbit antichicken IgG antibody (Santa
Cruz Biotech., Santa Cruz, CA, USA) were as the secondary
antibody, respectively.
2.4. Overexpression of r685A Protein In Vitro. In vitro
overexpression of r685A fusion protein was veriﬁed by
Western blot analysis of transfected HeLa cells. Cells were
cultured in wells of a 6-well plate and transfected with 1μg
of pcD685A or empty vector (pcDNA3.1). G418-resistant
colonies (250mg/L) were selected and harvested for the
Western blotting analysis with mouse polyclonal antibody to
r685A.
2.5. Immunogenicity of r685A Protein. The study protocol
was approved by the Ethics Committee of Tongji Medical
College. Written informed consents were obtained from all
subjects involvedin this study. Seventeenhousehold contacts
with recent sputum-positive TB patients (mean age: 37 ± 19
years; male/female ratio: 7/10) were enrolled. Active TB was
excluded for all household contacts based on radiologic and
clinical examinations, sputummicroscopy, and bacteriologic
culture. After heparinized whole blood sample from each
participants was collected, TSTand whole blood IFN-γ assay
(WBIA) based on the r685A protein were performed as
previously described, respectively [11]. Reactions of <5mm
and ≥5mm were considered TST negative and positive,
respectively. Whole blood from each donor (1mL) was
seededin 24-well platesand incubatedwith 20μL r685Apro-
tein at ﬁnal concentrations of 0 or 10μg/mL for 24h at 37◦C.
Afterstimulation,200μLofplasmawasthentakenfromeach
well and stored at −20◦C until use. The concentrations of
IFN-γ in collected samples were determined in duplicate,
using a commercial enzyme-linked immunosorbent assay
kit according to the manufacturer’s instructions (Dakewei
Biotech, Shenzhen, China).
2.6. Animal Immunization. Speciﬁc pathogen-free, 6- to 8-
week-old, female C57BL/6 mice (Vital River Lab Animal,
Beijing, China) were bred in cages on the animal feed-
ing cabinet (VentiRack, Chester, CA, USA) in a biosafety
level 3 laboratory. Mice received free access to food and
water throughout the study. The research protocol was
reviewed and approved by Tongji Medical School Commit-
tees on Biosaftey and Animal Care and Use Committee of
China.Clinical and Developmental Immunology 3
Table 1: Primers and thermal cycle parameters for cloningof M. tuberculosis antigens.
Protein
Names Primer names and sequences (5 -3 )C y c l e p a r a m e t e r s
ESAT-6
ESAT6F: GGATCCATGACAGAGCAGCAGTG
ESAT6R: GCTGCCGCCACCGCCGCTTCCGCCACCGCCGCTTCCACCGCC-
ACCTGCGAACATCCCAGTGACGTTGCCTTC
95◦C5 m i n ;9 4 ◦C4 5 s ,6 0 ◦C4 5 s ,
72◦C5 0s ,3 0c y c l e s ;7 2 ◦C1 0m i n
Ag85A
Ag85AF: GGTGGCGGTGGAAGCGGCGGTGGCGGAAGCGGCGGTGGCGGC-
AGCGCATTTTCCCGGCCGGGCTTG
Ag85AR: GGAATTCTGTTCGGAGCTAGGCGCCCTGGG
95◦C5 m i n ;9 4 ◦C4 5 s ,6 0 ◦C4 5 s ,
72◦C5 0s ,3 0c y c l e s ;7 2 ◦C1 0m i n
r685A ESAT6F
Ag85AR
95◦C5 m i n ;9 4 ◦C1 m i n ,6 0 ◦C
1min, 72 ◦C9 0 s ,3 0c y c l e s ;7 2 ◦C
10min
Mice were randomly divided into (12 mice in each
group): nonvaccinated control, vector control, pcD685A,
BCG, BCG prime plus vector booster, and BCG prime
plus pcD685A booster. Mice were injected with 30μLo f
0.25% Bupivacaine in the quadriceps muscle of each hind
leg three days before DNA immunization. Plasmid DNA
(50μg) was injected intramuscularly in the same area, and
immunizationwasrepeatedthricewith2-weekintervals.The
latter two groups were ﬁrstly immunized with 106 CFU BCG
once subcutaneously on the ﬁrst day, then boosted with the
plasmids following the DNA vaccination process. Two weeks
after the completion of gene immunization, ﬁve mice of each
groupwereusedforimmunologicalanalysis,whiletheothers
were challenged with virulent M. tuberculosis H37Rv.
2.7.Antibody Response. Sera were collectedfrom eachmouse
two weeks after immunization. Antigen-speciﬁc antibody
responses were measured in an ELISA using microtiter
plates, precoated overnight at 4◦C with 100μL r685A
protein (5μg/mL) in carbonate/bicarbonate buﬀer (pH 9.6).
After blocking with 1% BSA in PBS, serum samples were
diluted to appropriate concentrations and were incubated
for 2h at 37◦C. After washing, the plates were incubated
for 2h at 37◦C with HRP-conjugated goat antimouse IgG
antibody. Orthophenylenediamine (OPD)wasused forcolor
developmentas an indicator. Sera from naive mice were used
as negative controls. Data are presented as mean of optical
density value at 490nm per group.
2.8. qRT-PCR Analysis of IFN-γ and IL-10 Expression in
Lungs of Vaccinated Mice. About 100mg of lung tissue was
crushed with a syringe plunger and the DNA-free RNA
samples were extracted with TRIzol reagent (Invitrogen).
For qRT-PCR, 2μg of RNA was reverse transcribed with M-
MLV ReverseTranscriptase (Promega, USA)to obtain cDNA
samples. For the real-time reaction, each primer (250nM)
and 7.5μL of template reaction (1:20 dilution) in 25μL
volume with SYBR Green kit (Roche, USA) were used.
Triplicate samples were run on an Applied Rotor-Gene 3000
Real-Time system (Gene, USA).Tested cDNAswere normal-
ized to the endogenous RNA levels of the internal control
GAPDH. Gene expression was determined using the rela-
tive quantiﬁcation ΔΔCT = (CTTest − CTGAPDH)sample −
(CTTest − CTGAPDH)Control. CT is the fractional cyclenumber
that reaches a ﬁxed threshold, CTTest is the test of each
vaccinated group, and CTControl is the reference control
from the control group. ΔΔCT is the diﬀerence between
gene expression in each vaccinated group and the control
group. The increase fold was calculated using 2−ΔΔCT.
Primer sequences and cycle parameters used for qRT-PCR
are listed in Supplementary Table 1 (see Supplementary
Table 1 in Supplementary Material available online at
doi:10:1155/2011/61789g).
2.9. M. tuberculosis Challenge. C57BL/6 mice were infected
intravenously through the lateral tail vein at the dose of
106 CFU with exponentially growing M. tuberculosis sus-
pended in 100μL PBS. Four weeks later, seven mice per
group were killed, and bacterial burden was determined
by plating serial dilutions of lung and spleen homogenates
onto Middlebrook 7H11 agar plates supplemented with
10% (v/v) ADC enrichment and 0.5% (v/v) glycerol, con-
taining 2-thiophenecarboxylic acid hydrazide (10μg/mL),
which inhibits residual BCG but not M. tuberculosis.M o u s e
protocols were approved by the Biosafety Committee of
Tongji Medical College.
Right lung lobes from diﬀerent vaccine groups were
ﬁxed in 10% PBS-buﬀered formalin, embedded in paraﬃn,
sectioned and stained with hematoxylin and eosin (HE)
followed with analyzing by a pathologist with no prior
knowledge for the treatment group and recording the results
under a light microscope.
2.10.Statistical Analysis. Student’st testwas used tocompare
the mean organ burdensof each group ofmice, and a P value
w a sl e s st h a n. 0 5w a sc o n s i d e r e ds t a t i s t i c a l l ys i g n i ﬁ c a n t .
3.Results
3.1. Construction and Overexpression of Recombinant r685A
Protein in E. coli. The genes of ESAT-6 and Ag85A were
ﬁrst ampliﬁed by PCR and M. tuberculosis H37Rv genomic
DNA as the template (Figure 1) .T h ef u s i o ng e n eo fesat-
6 and fbpA was then ampliﬁed using a mixture of PCR
products of esat-6 and fbpA as template with the upstream
primer of ESAT-6 and the downstream primer of Ag85A
(Figure 1).The puriﬁed PCR productionswere digested with
BamHI and EcoRI and separately cloned into the plasmid4 Clinical and Developmental Immunology
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Figure 1: Construction of recombinant plasmids. Genes encoding
ESAT-6, Ag85A, the fusion protein of ESAT-6, and Ag85A with
a 45bp linker, were cloned from M. tuberculosis H37Rv genomic
DNA, respectively (A). The PCR products of the fusion genes
were inserted into the BamHI and EcoRI sites of pProExHTb or
pcDNA3.1, resulting in the recombinant plasmids pPro685A and
pcD685A, respectively. The recombinant plasmids were identiﬁed
by enzyme digestion (B).Lane M: DNA molecular marker; lane A1:
PCR product of esat-6;l a n eA 2 :P C Rp r o d u c to ffbpA;l a n eA 3 :P C R
product ofesat-6-fbpA;laneB1:productsofpPro685Adigestedwith
enzymes; lane B2: products of pcD685A digested with enzymes.
pProEXHTb and pcDNA3.1(+) predigested with the same
restriction enzymes, in order to construct prokaryotic
expression plasmid pPro685A and eukaryotic expression
plasmid pcD685A (Figure 1). DNA sequencing and enzyme
digestion conﬁrmed the successful constructions (Figure 1).
E. coli BL21 (DE3) strain containing plasmid pPro685A
was induced with IPTG, and recombinant fusion protein
r685A was identiﬁed by 12% SDS-PAGE with a molecular
mass of about 38kDa as expected (Figure 2). r685A protein
was expressed in E. coli in the inclusion body, and puriﬁca-
tion was performed using the Ni-NTA puriﬁcation system.
The process of puriﬁcation was monitored by SDS-PAGE
(Figure 2). The speciﬁcity of the puriﬁed r685A protein was
veriﬁed by Western blotting with anti-ESAT-6 and anti-
Ag85A antibodies, respectively, (Figure 2).
3.2. Expression of pcD685A DNA Construct. After plasmid
pcD685A was transfected into HeLa cells by electroporation,
cell lines of stable resistance to G418 were obtained by G418
selection. The expression of protein r685A was conﬁrmed
by Western blotting (Figure 3). HeLa cells transfected with
vector pcDNA3.1(+) were also detected as control and
showed the negative result as expected (Figure 3).
3.3. Immunogenicity of r685A Protein. Whole blood samples
were collected from 17 household contacts with active TB
patients and subjected to r685A-WBIA (Figure 4). The levels
of IFN-γ in all samples without antigen stimuli were below
30pg/mL (10.6 ± 5.9pg/mL) but signiﬁcantly increased
to 1401.1 ± 1084.3pg/mL after r685A protein stimulation.
Analysis of the distribution of IFN-γ levels in TST-positive
and TST-negative samples showed a signiﬁcant correlation
between TSTpositivity andIFN-γ level(Figure 4).The mean
IFN-γ levels in samples from TST-positive group detected by
r685A-WBIA were signiﬁcantly higher than those for TST-
negative group (P<. 05).
3.4. Antibody Response. Sera IgG antibodies against r685A
protein were determined by ELISA. As shown in Figure 5,
strong IgG response to r685A protein was elicited in BCG,
pcD685A, BCG plus vector, and BCG plus pcD685A-treated
mice groups. As expected, empty DNA vector and control
groups stimulated little or very weak IgG response.
3.5. Expression of IFN-γ and IL-10 in Lungs. To determine
cell-mediated immune responses in the lung, lung tissues
from immunized mice were prepared 2 weeks after the last
DNA vaccination. The expression levels of IFN-γ and IL-
10 in lungs of vaccinated mice were determined by qRT-
PCR. As shown in Figure 6,I F N - γ response increased in
all groups except the vector control group. Mice vaccinated
with BCG plus pcD685A induced the highest levels of IFN-γ
responses in the lungs. Combination with BCG increased
signiﬁcantly the expression of IFN-γ when compared with
BCG or pcD685A alone. In addition, BCG plus vector group
showed the most signiﬁcant IL10 response in the lung, and
high expression of IFN-γ was also produced. The expression
of both IFN-γ and IL-10 decreased in vector group when
compared with control mice.
3.6. BCG Prime Plus pcD685A Booster Produced Better Pro-
tective Eﬀect against Virulent Challenge of M. tuberculosis in
Mice than BCG Alone. In order to determine the protection
eﬀect, mice were challenged with M. tuberculosis H37Rv.
The results of bacterial load in diﬀerent organs were shown
in Figure 7. Most importantly, mice vaccinated with BCG
plus pcD685A produced the strongest protective eﬀect and
signiﬁcantly inhibited the growth of M. tuberculosis in the
lung (−1.922log) and spleen (−1.609log) when compared
withBCGorpcD685Aalone(P<. 05).Inaddition,pcD685A
also evoked a signiﬁcant protection (−0.663log) in the lung.
Highestbacterialloadwasseeninthelungandspleeninboth
control and empty vector groups.
3.7. Decreased Lung Pathology in Mice Vaccinated with
BCG Plus pcD685A Compared with BCG. Consistent with
varying bacterial loads in the lung, HE-stained sections
from diﬀerent groups showed clear diﬀerences (Figure 8).
The lung sections from both control and vector control
mice showed severe interstitial pneumonia and intense
inﬂammation throughout the lung with the appearance of
early granuloma formation (Figures 8(a) and 8(b)). Slight
damage in alveolar tissues with aggregated, relatively large
number of lymphocytes was also observed in the lung from
single pcD685A-vaccinated group (Figure 8(c)). BCG- andClinical and Developmental Immunology 5
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Figure 2: Expression, puriﬁcation, and identiﬁcation of recombinant fusion protein. E. coli BL21 (DE3) harboring pPro685A was cultured
with IPTG. The expression (a) and the puriﬁcation procession of r685A fusion protein (b) were conﬁrmed by SDS-PAGE and Western
blotting(c).LaneM:proteinmolecularsizemarker(kDa);lanea1:E. colistrainwithoutIPTG;lanea2:E. colistrain2hafterIPTGinduction;
lanea3:E. coli strain4hafterIPTGinduction;lanea4:E. colistrain6hafterIPTGinduction;laneb1:celllysis;laneb2:fractionfromNi-NTA
columnafter washwith denaturing binding buﬀer; lanes b3 and b4: fraction after wash with wash buﬀer; lane b5: r685A protein eluted with
native elution buﬀer; lane c1: anti-ESAT-6 antibody; lane c2: anti-Ag85A antibody.
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Figure 3: Western blot analysis of cell lysates from Hela cells
transfected with the pcD685A construct (lane 2) or empty vector
(lane 1). The primary antibody used was mouse antisera after
pcD685A DNA vaccination.
BCG plus vector-vaccinated mice showed slight interstitial
pneumonia (Figures 8(d) and 8(e)). Alveolar tissue from
mice vaccination with BCG plus pcD685A combination
appeared to be intact with very limited lung inﬂammation
(Figure 8(f)).
4.Discussion
Developing more eﬀective vaccines than BCG remains a
high priority in global TB control. The replacement of
currently used BCG with diﬀerent platforms might not be
a practical goal because it is the most widely used vaccine
in humans and has over 80% eﬃcacy against severe forms
of childhood TB, and because no other vaccine candidates
(based on diﬀerent platforms except BCG) are superior to
BCG so far. Therefore, a vaccine that can work as an eﬀective
booster of BCG vaccine may be ideal because it will be more
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Figure 4: Immunogenicity of r685A fusion protein in healthy
population.Atotalof17householdcontactswithactiveTB patients
were tested by TST and r685A-WBIA, respectively. Each square
represents the IFN-γ c o n c e n t r a t i o ni nas a m p l e ,a n dm e d i a nv a l u e s
for TST− (n = 7) and TST+ (n = 10) groups are indicated by
horizontallines.
eﬀective regardless of current vaccination strategy. In this
study, our data clearly demonstrated that mice vaccinated
with the recombinant plasmid pcD685A expressing the6 Clinical and Developmental Immunology
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Figure 5: r685A-speciﬁc IgG antibody-induced in immunized
mice. Mice were immunized and bled at day 14 following the last
immunization; serum antibody levels were assessed by ELISA. Sera
from ﬁve animals in each group were evaluated individually at the
dilutionsindicated. Results shownare the mean andstandard error.
fusion protein of ESAT6 and Ag85A markedly reduced the
bacterial load in the spleen and lung of vaccinated mice
when compared with control group, but did not increase
eﬃcacy over BCG. More importantly, BCG prime followed
by pcD685A DNA booster vaccination produced a greater
protection as shown by reduced bacterial load and more
pronounced antituberculous protective immune responses
than BCG or pcD685A alone. The results of IFN-γ assay
in a TST-positive population, cytokines assay of the lungs,
postchallenge lung and spleen bacterial load, and patholog-
ical examination indicate that BCG prime plus pcD685A
booster is an eﬀective vaccine strategy against murine
TB.
The antigen Ag85 complex was shared in by M. tuber-
culosis, BCG, and other mycobacteria, consisting of a family
of three proteins (Ag85A, Ag85B, and Ag85C) with a MW
range of 30–32000 daltons [12, 13]. These proteins possess
mycolyl-transferase activity, which are responsible for the
transfer of mycolic acids to a-a -trehalose to form the cord
factor and play an important role in the biogenesis of cell
wall of mycobacteria [14]. The gene for ESAT-6 is absent
in all BCG strains distributed worldwide, but is present
in M. tuberculosis complex [15]. ESAT-6 is considered a
dominant antigen for cell-mediated immunity [16]a n di s
a major target for memory T cells in mice infected with
M. tuberculosis [17]. Recently, diﬀerent gene transferring
systems such as modiﬁed vaccinia virus Ankara [18],
alphavirus [19], vaccinia [20], or adenovirus [21, 22], BCG
[23], and plasmid DNA [24–27] have been used to express
Ag85A. The results of these studies showed that Ag85A can
induce humoral and cell-mediated immunity and provide
signiﬁcant protection against TB in diﬀerent animal models.
Subunitvaccine based onantigen ESAT-6also couldenhance
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Figure 6: Diﬀerential expression of IFN-γ and IL-10 in the lungs
of vaccinated mice (n = 3). Two weeks after DNA vaccination,
RNA extracted from lung of each mouse in diﬀerent groups was
used for the detection of cytokines mRNA concentrations by
qRT-PCR analysis. The levels of the cytokine mRNAs for each
group were normalized based on the levels of GAPDH. Cytokine
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Figure 7: Bacterial load per lung and spleen in C57BL/6 mice
at 4 weeks after challenge (n = 7). Vaccinated C57BL/6 mice
(n = 7) were challenged i.v. with 106 CFU virulent M. tuber-
culosis H37Rv strain. Four weeks after challenge, lungs and
spleens were harvested aseptically and numbers of bacterial CFU
per organ were enumerated. Results are shown as the mean
(±SEM) log10 CFU/organ. ∗P<. 05 versus control; ∗∗P<. 05
versus BCG. This experiment was repeated twice with similar
results.Clinical and Developmental Immunology 7
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Figure 8: Representative lung pathology of C57BL/6 mice after challenge. Vaccinated C57BL/6 mice were challenged i.v with 106 CFU
virulent Mycobacterium tuberculosis H37Rv strain. Four weeks after infection, lung tissue sections from diﬀerent vaccine groups were
prepared for HE staining (ampliﬁcation 10 × 4), (a) control; (b) vector control; (c) pcD685A; (d) BCG; (e) BCG plus vector; (f) BCG
plus pcD685A.8 Clinical and Developmental Immunology
the eﬃcacy of BCG [9], and the vaccine of the fusion
protein of ESAT-6 with Ag85B which promotes strong
and long-lived M. tuberculosis-speciﬁc T cell responses in
na¨ ıve human volunteers has been evaluated in clinical study
[28]. Recombinant BCG expressing ESAT-6 also conferred
enhanced immunogenicity and protection against TB when
compared with the parent BCG vaccine [29, 30]. Other vac-
cine platforms such as DNA vaccine [31–33], Inﬂuenza virus
[34], and Salmonella typhimurium [35] also demonstrated
that ESAT-6 is a potential immunodominant antigen for
the development of TB vaccines. In addition, a chimeric
protein of Ag85A and ESAT-6 with strong immunogenicity
showed a treatment eﬀe c to nM D R - T Bi nm i c e[ 36, 37].
In order to combine the immunological advantage of both
antigens, we designed the fusion protein of Ag85A and
ESAT-6 with a linker of 15 amino acid peptides, aimed to
keep the naive conﬁguration of these proteins. With the
stimulation of puriﬁed r685A fusion protein, IFN-γ level
in the peripheral blood from the TST-positive household
contacts was much higher than that of TST negative group.
Without the stimulation of r685A protein, IFN-γ levels in
both groups are very low or none. These results indicate that
the production of IFN-γ in the peripheral blood is r685A
antigen speciﬁc and that r685A could stimulate the release
of IFN-γ from sensitized T lymphocytes in the peripheral
bloodofhouseholdcontacts.IFN-γ isanimportantindicator
for Th1-type cellular immune response and is an essential
mediator of the protective immune response to TB [38].
Therefore, we assume that the expression of r685A protein
in vivo might be a promising stimulator of Th1-type
cellular immune response against TB and might amplify the
protectiveeﬃcacyofBCG.Inthisstudy,pcD685Aexpressing
r685A protein can protect mice against a primary M.
tuberculosis infection with comparable pathological changes
in lung with BCG, although bacterial load of lung and
spleen in pcD685A vaccinated mice was higher than that of
BCG.
Previous studieshave shown that repeat vaccination with
BCG may be deleterious to protection against TB [39], and
heterologous boost vaccines are likely to be used to enhance
speciﬁc immunity primed by BCG [40]b e c a u s eB C Gi s
not an eﬀective booster vaccine itself. Several studies have
demonstrated that recombinant modiﬁed vaccinia virus or
adenovirus expressing Ag85A could enhance the waning
BCGimmunity and both havebeen underclinicalevaluation
[41, 42]. DNA vaccine expressing ESAT-6 [43]o rt h ef u s i o n
protein of Ag85B with ESAT-6 also could amplify the
protective immune responses of BCG prime [44, 45]. In
our study, BCG prime and pcD685A booster showed the
greatest protection against M. tuberculosis infection in mice.
pcD685A could amplify antituberculous protective immune
response in mice previously vaccinated with BCG, and
markedly enhanced protection was correlated with increased
IFN-γ level in the lungs of mice models prior to challenge.
Although the gene encoding ESAT-6 is deleted in BCG,
ESAT-6 may amplify overall anti-TB immunity in BCG
immune animals by activating ESAT-6-speciﬁc T cells and
play an important role in producing the booster eﬀect of
r685A protein.
5.Conclusion
Inthisstudy,ourresultsclearlydemonstratedthevaccination
of C57BL/6 mice with DNA vaccine (pcD685A) expressing
the fusion protein of Ag85A and ESAT-6 (r685A). pcD685A
resulted in signiﬁcant protection against challenge with
virulent M. tuberculosis H37Rv when compared with the
control group. Most importantly, BCG prime and pcD685A
booster resulted inthemost signiﬁcant reductionin bacterial
load of both spleen and lung when compared with BCG or
pcD685Aalone.Thus,ourstudyindicatesthatpcD685Amay
beaneﬃcientboostervaccineagainstTBwithastrongability
to enhance prior BCG immunity.
Acknowledgments
This work was supported by grants of the Fok Ying Tung
Education Foundation (no. 114032), the National High
Technology Research and Development of China (863 pro-
gram no. 2006AA02Z445), and the National Mega-Projects
of Science Research for the 11th Five-Year Plan (2008ZX-
10003-013). J. Lu, C. Wang, and Z. Zhou contributedequally
to this work.
References
[1] WHO,“Globaltuberculosis control:ashortupdate tothe2009
report,” WHO Report, Geneva, Switzerland, 2009.
[2] N. R. Gandhi, A. Moll, A. W. Sturm et al., “Extensively
drug-resistant tuberculosis as a cause of death in patients co-
infected with tuberculosis and HIV in a rural area of South
Africa,” Lancet, vol. 368, no. 9547, pp. 1575–1580, 2006.
[3] “BCG vaccine. WHO position paper,” The Weekly Epidemio-
logical Record, vol. 79, pp. 27–38, 2004.
[ 4 ]B .B .T r u n z ,P .F i n e ,a n dC .D y e ,“ E ﬀect of BCG vaccination
on childhood tuberculous meningitis and miliary tubercu-
losis worldwide: a meta-analysis and assessment of cost-
eﬀectiveness,” Lancet, vol. 367, no. 9517, pp. 1173–1180,2006.
[ 5 ]P .E .M .F i n e ,I .A .M .C a r n e i r o ,J .B .M i l s t i e n ,a n dC .J .
Clements,“IssuesRelating totheUseofBCGinImmunization
Programmes,” WHO, Geneva, Switzerland, 1999.
[6] M. Romanoand K. Huygen, “DNA vaccines againstmycobac-
terial diseases,” Expert Review of Vaccines,v o l .8 ,n o .9 ,p p .
1237–1250, 2009.
[7] C. Rouanet and C. Locht, “Boosting BCG to protect against
TB,” Expert Review of Respiratory Medicine,v o l .4 ,n o .3 ,p p .
339–348, 2010.
[ 8 ]X .F a n ,Q .G a o ,a n dR .F u ,“ D i ﬀerential immunogenicity and
protective eﬃcacy of DNA vaccines expressing proteins of
Mycobacterium tuberculosis inamousemodel,”Microbiological
Research, vol. 164, no. 4, pp. 374–382, 2009.
[9] X. Fan, Q. Gao, and R. Fu, “DNA vaccine encoding ESAT-
6e n h a n c e st h ep r o t e c t i v ee ﬃcacy of BCG against Mycobac-
terium tuberculosis infection in mice,” Scandinavian Journal of
Immunology, vol. 66, no. 5, pp. 523–528, 2007.
[ 1 0 ]R .M .H o r t o n ,H .D .H u n t ,S .N .H o ,J .K .P u l l e n ,a n dL .R .
Pease,“Engineeringhybridgeneswithouttheuseofrestriction
enzymes:genesplicingbyoverlapextension,”Gene,vol.77,no.
1, pp. 61–68, 1989.
[11] R. Fu, C. Wang, C. Shi et al., “An improved whole-blood
gamma interferon assay based on the CFP21-MPT64 fusionClinical and Developmental Immunology 9
protein,” Clinical and Vaccine Immunology,v o l .1 6 ,n o .5 ,p p .
686–691, 2009.
[12] J. Content, A. De La Cuvellerie, L. De Wit, V. Vincent-Levy-
Frebault, J. Ooms, and J. De Bruyn, “The genes coding for
the antigen 85 complexes of Mycobacterium tuberculosis and
Mycobacterium bovis BCG are members of a gene family:
cloning, sequence determination, and genomic organization
of the gene coding for antigen 85-C of M. tuberculosis,”
Infection and Immunity, vol. 59, no. 9, pp. 3205–3212, 1991.
[13] H. G. Wiker and M. Harboe, “The antigen 85 complex:
a major secretion product of Mycobacterium tuberculosis,”
Microbiological Reviews, vol. 56, no. 4, pp. 648–661, 1992.
[ 1 4 ]J .T .B e l i s l e ,V .D .V i s s a ,T .S i e v e r t ,K .T a k a y a m a ,P .J .B r e n n a n ,
and G. S. Besra, “Role of the major antigen of Mycobacterium
tuberculosis in cell wall biogenesis,” Science, vol. 276, no. 5317,
pp. 1420–1422, 1997.
[15] M. A. Behr, M. A. Wilson, W. P. Gill et al., “Comparative
genomics of BCG vaccines by whole-genome DNA microar-
ray,” Science, vol. 284, no. 5419, pp. 1520–1523, 1999.
[16] L. Brandt, M. Elhay, I. Rosenkrands, E. B. Lindblad, and
P. Andersen, “ESAT-6 subunit vaccination against Mycobac-
terium tuberculosis,” Infection and Immunity,v o l .6 8 ,n o .2 ,p p .
791–795, 2000.
[17] P. Andersen, A. B. Andersen, A. L. Sorensen, and S. Nagai,
“Recall of long-lived immunity to Mycobacterium tuberculosis
infection in mice,” Journal of Immunology, vol. 154, no. 7, pp.
3359–3372, 1995.
[18] H.McShane,A.A.Pathan,C.R.Sander,N.P.Goonetilleke,H.
A. Fletcher, and A. V. S. Hill, “Boosting BCG with MVA85A:
the ﬁrst candidate subunit vaccine for tuberculosis in clinical
trials,” Tuberculosis, vol. 85, no. 1-2, pp. 47–52, 2005.
[ 1 9 ]J .R .K i r m a n ,T .T u r o n ,H .S ue ta l . ,“ E n h a n c e di m m u n o -
genicity to Mycobacterium tuberculosis by vaccination with an
alphavirus plasmidreplicon expressing antigen 85A,” Infection
and Immunity, vol. 71, no. 1, pp. 575–579, 2003.
[20] A. S. Malin, K. Huygen, J. Content et al., “Vaccinia expres-
sion of Mycobacterium tuberculosis-secreted proteins: tissue
plasminogen activator signal sequence enhances expression
and immunogenicity of M. tuberculosis Ag85,” Microbes and
Infection, vol. 2, no. 14, pp. 1677–1685, 2000.
[ 2 1 ]J .W a n g ,L .T h o r s o n ,R .W .S t o k e se ta l . ,“ S i n g l em u c o s a l ,b u t
not parenteral, immunization with recombinant adenoviral-
based vaccine provides potent protection from pulmonary
tuberculosis,” Journal of Immunology, vol. 173, no. 10, pp.
6357–6365, 2004.
[22] K. Radosevic, C. W. Wieland, A. Rodriguez et al., “Protective
immune responses to a recombinant adenovirus type 35
tuberculosis vaccine in two mouse strains: CD4 and CD8 T-
cell epitope mapping and role of gamma interferon,” Infection
and Immunity, vol. 75, no. 8, pp. 4105–4115, 2007.
[23] I. Sugawara, Z. Li, L. Sun, T. Udagawa, and T. Taniyama,
“Recombinant BCG Tokyo (Ag85A) protects cynomolgus
monkeys(Macaca fascicularis) infected with H37Rv Mycobac-
terium tuberculosis,” Tuberculosis, vol. 87, no. 6, pp. 518–525,
2007.
[ 2 4 ]A .T a n g h e ,O .D e n i s ,B .L a m b r e c h t ,V .M o t t e ,T .V a nD e n
Berg, and K. Huygen, “Tuberculosis DNA vaccine encoding
Ag85A is immunogenic and protective when administered by
intramuscularneedle injection but notby epidermal gene gun
bombardment,” Infection and Immunity,v o l .6 8 ,n o .7 ,p p .
3854–3860, 2000.
[25] S. L. Baldwin, C. D. D’Souza, I. M. Orme et al., “Immuno-
genicity and protective eﬃcacy of DNA vaccines encoding
secreted and non-secreted forms of Mycobacterium tuberculo-
sis Ag85A,” Tubercle and Lung Disease, vol. 79, no. 4, pp. 251–
259, 1999.
[26] E. Lozes, K. Huygen, J. Content et al., “Immunogenicity
and eﬃcacy of a tuberculosis DNA vaccine encoding the
components of the secreted antigen 85 complex,” Vaccine,v o l .
15, no. 8, pp. 830–833, 1997.
[27] D. L. Montgomery, K. Huygen, A. M. Yawman et al., “Induc-
tionofhumoralandcellularimmuneresponsesbyvaccination
with M. tuberculosis antigen 85 DNA,” Cellular and Molecular
Biology, vol. 43, no. 3, pp. 285–292, 1997.
[28] J. T. van Dissel, S. M. Arend, C. Prins et al., “Ag85B-ESAT-
6a d j u v a n t e dw i t hI C 3 1p r o m o t e ss t r o n ga n dl o n g - l i v e d
Mycobacterium tuberculosis speciﬁc T cell responses in na¨ ıve
human volunteers,” Vaccine, vol. 28, no. 20, pp. 3571–3581,
2010.
[ 2 9 ]A .S .P y m ,P .B r o d i n ,L .M a j l e s s ie ta l . ,“ R e c o m b i n a n t
BCG exporting ESAT-6 confers enhanced protection against
tuberculosis,” Nature Medicine, vol. 9, no. 5, pp. 533–539,
2003.
[ 3 0 ]L .M .W a n g ,C .H .S h i ,X .L .F a n ,Y .X u e ,Y .L .B a i ,a n d
Z. K. Xu, “Expression and immunogenicity of recombinant
Mycobacterium bovis Bacillus Calmette-Gu´ erin strains secret-
ing the antigen ESAT-6 from Mycobacterium tuberculosis in
mice,” Chinese Medical Journal, vol. 120, no. 14, pp. 1220–
1225, 2007.
[ 3 1 ]Q .M .W a n g ,L .K a n g ,a n dX .H .W a n g ,“ I m p r o v e dc e l l u l a r
immune response elicited by a ubiquitin-fused ESAT-6 DNA
vaccine against Mycobacterium tuberculosis,” Microbiology and
Immunology, vol. 53, no. 7, pp. 384–390, 2009.
[32] A. Dey, U. Kumar, P. Sharma, and S. Singh, “Immunogenicity
of candidate chimeric DNA vaccine against tuberculosis and
leishmaniasis,”Vaccine, vol. 27, no. 37, pp. 5152–5160, 2009.
[33] O. Nosareva, A. Nesterov, A. Boldyrev et al., “Construction of
anencapsulatedESAT-6-basedanti-TBDNAvaccineandeval-
uation of its immunogenic properties,” Biological Chemistry,
vol. 389, no. 5, pp. 579–583, 2008.
[34] F. Krammer, T. Schinko, P. Messner, D. Palmberger, B. Ferko,
and R. Grabherr, “Inﬂuenza virus-like particles as an antigen-
carrier platform for the ESAT-6 epitope of Mycobacterium
tuberculosis,” Journal of Virological Methods,vol.167,no.1,pp.
17–22, 2010.
[35] H. J. Mollenkopf, D. Groine-Triebkorn, P. Andersen, J. Hess,
and S. H. E. Kaufmann, “Protective eﬃcacy against tuber-
culosis of ESAT-6 secreted by a live Salmonella typhimurium
vaccine carrier strain and expressed by naked DNA,” Vaccine,
vol. 19, no. 28-29, pp. 4028–4035, 2001.
[ 3 6 ]Z .L i ,H .Z h a n g ,X .F a ne ta l . ,“ D N Ae l e c t r o p o r a t i o np r i m e
and protein boost strategy enhances humoral immunity of
tuberculosis DNAvaccinesinmiceandnon-humanprimates,”
Vaccine, vol. 24, no. 21, pp. 4565–4568, 2006.
[37] Y. Liang, X. Wu, J. Zhang et al., “The treatment of mice
infected with multi-drug-resistant Mycobacterium tuberculosis
using DNA vaccines or in combination with rifampin,”
Vaccine, vol. 26, no. 35, pp. 4536–4540, 2008.
[38] S. H. E. Kaufmann, “How can immunology contribute to the
control of tuberculosis?” Nature Reviews Immunology,v o l .1 ,
no. 1, pp. 20–30, 2001.
[39] L. C. Rodrigues, S. M. Pereira, S. S. Cunha et al., “Eﬀect of
BCG revaccination on incidence of tuberculosis in school-
aged children in Brazil: the BCG-REVAC cluster-randomised
trial,” Lancet, vol. 366, no. 9493, pp. 1290–1295, 2005.10 Clinical and Developmental Immunology
[40] S. H. E. Kaufmann, “Recent ﬁndings in immunology give
tuberculosis vaccines a new boost,”Trends in Immunology,v ol.
26, no. 12, pp. 660–667, 2005.
[41] H. M. Vordermeier, S. G ¸.R h o d e s ,G ¸ . Dean et al., “Cellular
immune responses induced in cattle by heterologous prime-
boost vaccination using recombinant viruses and bacille
Calmette-Gu´ erin,” Immunology, vol. 112, no. 3, pp. 461–470,
2004.
[42] M. Santosuosso, S. McCormick, X. Zhang, A. Zganiacz,
and Z. Xing, “Intranasal boosting with an adenovirus-
vectored vaccine markedly enhances protection by parenteral
Mycobacterium bovis BCG immunization against pulmonary
tuberculosis,” Infection and Immunity,vol.74,no.8,pp. 4634–
4643, 2006.
[43] B. Dey, R. Jain, A. Khera et al., “Boosting with a DNA
vaccineexpressingESAT-6(DNAE6)obliteratestheprotection
imparted by recombinant BCG (rBCGE6) against aerosol
Mycobacterium tuberculosis infection in guinea pigs,” Vaccine,
vol. 28, no. 1, pp. 63–70, 2009.
[ 4 4 ]S .C .D e r r i c k ,A .L .Y a n g ,a n dS .L .M o r r i s ,“ Ap o l y v a l e n t
DNA vaccine expressing an ESAT6-Ag85B fusion protein
protects mice against a primary infection with Mycobacterium
tuberculosis and boosts BCG-induced protective immunity,”
Vaccine, vol. 23, no. 6, pp. 780–788, 2004.
[45] J. Dietrich, C. Andersen, R. Rappuoli, T. M. Doherty, C. G.
Jensen, and P. Andersen, “Mucosal administration of Ag85B-
ESAT-6 protects against infection with Mycobacterium tuber-
culosis and boosts prior bacillus Calmette-Gu´ erin immunity,”
Journal of Immunology, vol. 177, no. 9, pp. 6353–6360, 2006.